New Clinical Trial for Non-Small Cell Lung Cancer Offered by the Oncology Institute of Hope and Innovation
The Oncology Institute of Hope and Innovation announces a new clinical trial available for individuals with Non-Small Cell Lung Cancer.
Downey, Calif. (PRWEB) November 19, 2012
The Oncology Institute of Hope and Innovation is proud to have access to the latest research, technology and treatment options, including clinical trials for eligible patients. They are dedicated to providing comprehensive medical services to their patients. In their quest to be at the forefront of the latest medical cancer research, the institute participates in numerous clinical trials focused on various types of malignancies that may be of interest to oncology patients. They are pleased to make the announcement of the following clinical trial for individuals with non-small cell lung cancer which may benefit some of your patients:
Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC). This is a 3-part Phase 1-2 Study in Subjects with Anaplastic Lymphoma Kinase (ALK) + or other Potentially Crizotinib-sensitive NSCLC who have been Receiving Crizotinib.
The primary objective is to establish the safety and maximum tolerated dose of AT13387 when administered in combination with crizotinib as well as to compare the efficacy between the continued administration of single-agent crizotinib and the combination of crizotinib + AT13387 in subjects with non-small cell lung cancer (NSCLC) who were treated for at least 8 weeks with crizotinib and have not had a complete response or progressed.
They are currently the only site open for accrual in the United States.
Patients who may qualify for the trial or have questions regarding eligibility can contact any one of their 9 locations to schedule an evaluation.
About The Oncology Institute:
The Oncology Institute of Hope and Innovation is committed to providing superior, compassionate and state-of-the-art medical care. Offering programs to help patients and families cope with the challenges that are brought on by cancer and strive to optimize their quality of life, comprehensive and realistic treatment goals are tailored to every person's unique needs and decided upon in partnership with the patients and their families. Dedicated to excel in cancer prevention, diagnosis and education through our exceptional team of physicians, nurse practitioners, nurses, medical assistants and office staff, The Oncology Institute of Hope and Innovation has 9 Southern California locations in the cities of Anaheim, Downey, Glendale, Long Beach, Lynwood, Montebello, Torrance, Santa Ana, and Whittier. For more information please visit http://www.theoncologyinstitute.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/11/prweb10151211.htm